Abstract
Symptom provocation has proved its worth for understanding the pathophysiology of diseases and in general for the development of new therapeutic approaches in the medical field. In the research of anxiety disorders, investigations using experimentally induced panic attacks by various agents, such as sodium lactate, carbon dioxide, cholezystokinine-tetrapetid etc., have a long tradition and allow the exploration of usually naturally occuring spontaneous psychopathological phenomena under controlled conditions. Post-Traumatic Stress Disorder (PTSD) is a prevalent disorder that can develop following exposure to an extreme traumatic event. In DSM-IV it is currently classified as an anxiety disorder and shares phenomenological similarities with panic disorder. The use of panicogenic challenge tests is also an interesting neurobiological approach to learn more about the nature of PTSD and may be a possibility to develop new therapeutic strategies for the treatment of PTSD symptoms. Not only panic anxiety, but also flashbacks and other dissociative symptoms can be provoked by several panicogens in PTSD. The purpose of this review is to evaluate studies using panicogens in PTSD. Methodological short-comings of current studies and needed directions of further research are discussed.
Keywords: PTSD, panic, panicogen, flashback, lactate, CCK-4, CO2, flumazenil, m-CPP, yohimbine
Current Pharmaceutical Design
Title:Panicogens in Patients with Post-Traumatic Stress Disorder (PTSD)
Volume: 18 Issue: 35
Author(s): Christoph Muhtz, Klaus Wiedemann and Michael Kellner
Affiliation:
Keywords: PTSD, panic, panicogen, flashback, lactate, CCK-4, CO2, flumazenil, m-CPP, yohimbine
Abstract: Symptom provocation has proved its worth for understanding the pathophysiology of diseases and in general for the development of new therapeutic approaches in the medical field. In the research of anxiety disorders, investigations using experimentally induced panic attacks by various agents, such as sodium lactate, carbon dioxide, cholezystokinine-tetrapetid etc., have a long tradition and allow the exploration of usually naturally occuring spontaneous psychopathological phenomena under controlled conditions. Post-Traumatic Stress Disorder (PTSD) is a prevalent disorder that can develop following exposure to an extreme traumatic event. In DSM-IV it is currently classified as an anxiety disorder and shares phenomenological similarities with panic disorder. The use of panicogenic challenge tests is also an interesting neurobiological approach to learn more about the nature of PTSD and may be a possibility to develop new therapeutic strategies for the treatment of PTSD symptoms. Not only panic anxiety, but also flashbacks and other dissociative symptoms can be provoked by several panicogens in PTSD. The purpose of this review is to evaluate studies using panicogens in PTSD. Methodological short-comings of current studies and needed directions of further research are discussed.
Export Options
About this article
Cite this article as:
Muhtz Christoph, Wiedemann Klaus and Kellner Michael, Panicogens in Patients with Post-Traumatic Stress Disorder (PTSD), Current Pharmaceutical Design 2012; 18 (35) . https://dx.doi.org/10.2174/138161212803530817
DOI https://dx.doi.org/10.2174/138161212803530817 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cognitive Remediation Therapy of Social Cognition in Schizophrenia: A Critical Review
Current Psychiatry Reviews Immunophilins and Coupled Gating of Ryanodine Receptors
Current Topics in Medicinal Chemistry The Physicochemical and Pharmacokinetic Relationships of Barbiturates – From the Past to the Future
Current Pharmaceutical Design Endocannabinoids in Neuroimmunology and Stress
Current Drug Targets - CNS & Neurological Disorders Melatonin Effects in REM Sleep Behavior Disorder Associated with Obstructive Sleep Apnea Syndrome: A Case Series
Current Alzheimer Research New Prospects for Glycopeptide Based Analgesia: Glycoside-Induced Penetration of the Blood-Brain Barrier
Current Drug Delivery Aerobic Exercise for Preventing Osteoporosis in Postmenopausal Women: an Update of its Effect on Bone Mineral Density
Current Rheumatology Reviews Protein Aggregation in Alzheimers Disease and Other Neoropathological Disorders
Current Alzheimer Research Clinical Pharmacology of Cyclophosphamide and Ifosfamide
Current Drug Therapy Grape Seed Proanthocyanidins Protect N2a Cells against Ischemic Injury via Endoplasmic Reticulum Stress and Mitochondrial-associated Pathways
CNS & Neurological Disorders - Drug Targets Recent Advances in the Structure-Based and Ligand-Based Design of IKKβ Inhibitors as Anti-inflammation and Anti-cancer Agents
Current Medicinal Chemistry Naturally Inspired Pyrimidines Analogues for Alzheimer’s Disease
Current Neuropharmacology Prospective Role of MicroRNAs in Depression
Current Medicinal Chemistry Dynamic Simulation, Docking and DFT Studies Applied to a Set of Anti-Acetylcholinesterase Inhibitors in the enzyme β-Secretase (BACE-1): An Important Therapeutic Target in Alzheimer's Disease
Current Computer-Aided Drug Design Peptoids: Bio-Inspired Polymers as Potential Pharmaceuticals
Current Pharmaceutical Design Putative Involvement of Endocrine Disruptors in the Alzheimer's Disease Via the Insulin-Regulated Aminopeptidase/GLUT4 Pathway
Current Neuropharmacology Conantokins: Peptide Antagonists of NMDA Receptors
Current Medicinal Chemistry A Novel Fluorescence-Labeled Curcumin Conjugate: Synthesis, Evaluation and Imaging on Human Cell Lines
Current Pharmaceutical Design Gap Junctions as Therapeutic Targets in Brain Injury Following Hypoxia- Ischemia
Recent Patents on CNS Drug Discovery (Discontinued) Cellular Mechanisms of Striatum-Dependent Behavioral Plasticity and Drug Addiction
Current Molecular Medicine